Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Vs. Tacrolimus and Methotrexate As Graft-Versus-Host Disease Prevention Among Allogeneic Stem Cell Transplant Patients Receiving Myeloablative Conditioning | Synapse
March 3, 2026
Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Vs. Tacrolimus and Methotrexate As Graft-Versus-Host Disease Prevention Among Allogeneic Stem Cell Transplant Patients Receiving Myeloablative Conditioning
Puntos clave
Graft-versus-host disease prevention was more effective with post-transplant cyclophosphamide.
A significant reduction in graft-versus-host disease was observed when combining cyclophosphamide, tacrolimus, and mycophenolate.
Analysis of treatment outcomes focuses on allogeneic stem cell transplant patients receiving myeloablative conditioning.
These findings may call for new standards in preventing graft-versus-host disease, enhancing patient care.